A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG<sub>4</sub> to allergens from all trees in the birch homologous group

Couroux, Peter; Ipsen, Henrik; Stage, Brian Sonne; Damkjaer, Jakob Thomas; Steffensen, Maria Abildgaard; Salapatek, Anne Marie; Lund, Kaare; Würtzen, Peter Adler

doi:10.1111/all.13606

Cited by 64 publications

(76 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum IgG4 levels are typically very low, but following AIT, they can rise dramatically resulting in an increased IgG4/IgE ratio. 9 Other Ig isotypes are also found to increase, possibly contributing to the serum inhibitory activity on allergen-IgE binding. 11,21,40 Indeed, the reduction in IgE-facilitated allergen binding (IgE-FAB) following grass pollen SLIT was found to be associated with increased specific IgG1 and IgA as well as IgG4 in serum.…”

Section: Immunoglobulinsmentioning

confidence: 97%

“…7 Conventionally, AIT for aeroallergens is given by subcutaneous injections subcutaneous immunotherapy (SCIT) 8 or sublingually sublingual immunotherapy (SLIT). 9,10 These approaches are deemed safe, but in a minority of patients, a strong reaction can already be observed at the (very low) starting dose, postponing or stopping further therapy. Furthermore, it has become evident that at least 3 years of treatment is needed to confer long-term clinical tolerance.…”

Section: Allergen Immunotherapy: a Prototype Of Precision Medicinementioning

confidence: 99%

“…Conventionally, AIT for aeroallergens is given by subcutaneous injections (SCIT) or sublingually (SLIT) . These approaches are deemed safe, but in a minority of patients, a strong reaction can already be observed at the (very low) starting dose, postponing or stopping further therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recent developments and highlights in immune monitoring of allergen immunotherapy

Zelm

McKenzie

Varese

et al. 2019

Allergy

View full text Add to dashboard Cite

Allergic diseases are the most common chronic immune-mediated disorders and can manifest with an enormous diversity in clinical severity and symptoms. Underlying mechanisms for the adverse immune response to allergens and its downregulation by treatment are still being revealed. As a result, there have been, and still are, major challenges in diagnosis, prediction of disease progression/evolution and treatment.Currently, the only corrective treatment available is allergen immunotherapy (AIT).AIT modifies the immune response through long-term repeated exposure to defined doses of allergen. However, as the treatment usually needs to be continued for several years to be effective, and can be accompanied by adverse reactions, many patients face difficulties completing their schedule. Long-term therapy also potentially incurs high costs. Therefore, there is a great need for objective markers to predict or to monitor individual patient's beneficial changes in immune response during therapy so that efficacy can be identified as early as possible. In this review, we specifically address recent technical developments that have generated new insights into allergic disease pathogenesis, and how these could potentially be translated into routine laboratory assays for disease monitoring during AIT that are relatively inexpensive, robust and scalable. K E Y W O R D Sallergen immunotherapy, allergy, biomarker, immune monitoring | 2343 ZELM Et aL.

show abstract

Section: Immunoglobulinsmentioning

confidence: 97%

Section: Allergen Immunotherapy: a Prototype Of Precision Medicinementioning

confidence: 99%

See 1 more Smart Citation

Recent developments and highlights in immune monitoring of allergen immunotherapy

Zelm

McKenzie

Varese

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…Allergen‐specific immunotherapy is usually given as subcutaneous injections or sublingually, but novel treatment forms such as peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens, and immune‐modulating adjuvants and nanoparticles are under development.…”

Section: Unmet Needs and Future Research Areas In Treatment Of Allergmentioning

confidence: 99%

“…213 Moreover, there is some evidence that AIT is cost-effective in AR with or without asthma. 214 Allergen-specific immunotherapy is usually given as subcutaneous injections 215,216 or sublingually, [217][218][219] but novel treatment forms such as peptide immunotherapy, 11,220 intralymphatic immunotherapy 11,220 and use of recombinant allergens, and immune-modulating adjuvants and nanoparticles 21,220,221 are under development.…”

Section: Novel Therapeutic Concepts In Ait For Airway Diseasementioning

confidence: 99%

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Breiteneder

Diamant

Eiwegger

et al. 2019

Allergy

101

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractThe specialties of allergy and clinical immunology have entered the era of precision medicine with the stratification of diseases into distinct disease subsets, specific diagnoses, and targeted treatment options, including biologicals and small molecules.This article reviews recent developments in research and patient care and future trends in the discipline. The section on basic mechanisms of allergic diseases summarizes the current status and defines research needs in structural biology, type 2 inflammation, immune tolerance, neuroimmune mechanisms, role of the microbiome and diet, environmental factors, and respiratory viral infections. In the section on diagnostic challenges, clinical trials, precision medicine and immune monitoring Zuzana Diamanthttps://orcid.org/0000-0003-0133-0100Thomas Eiwegger https://orcid.org/0000-0002-2914-7829Wytske J. Fokkens https://orcid.org/0000-0003-4852-229X

show abstract

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

105

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG₄ to allergens from all trees in the birch homologous group

Cited by 64 publications

References 22 publications

Recent developments and highlights in immune monitoring of allergen immunotherapy

Recent developments and highlights in immune monitoring of allergen immunotherapy

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About

A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group

Cited by 64 publications

References 22 publications

Recent developments and highlights in immune monitoring of allergen immunotherapy

Recent developments and highlights in immune monitoring of allergen immunotherapy

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About

A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG₄ to allergens from all trees in the birch homologous group